Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2001

View Archived Issues

NewBiotics and Elan form joint venture to develop colon cancer therapy

Collgard and Mayo Clinic sign second agreement for halofuginone development

North American trial to evaluate Xenical in overweight adolescents

Centocor files IND for fully human antibody product

Phase II study examines IMC-C225 in combination with other agents for NSCLC

Selective or nonselective ET antagonists for pulmonary hypertension?

Novel DNA crosslinker with potential in the treatment of cisplatin-resistant ovarian cancer

Lexicon Genetics delivers antigens to Abgenix in antibody development alliance

Landmark HIP trial shows risedronate reduces risk of hip fracture in elderly women with osteoporosis

Lundbeck seeks first approval of Cipralex in Sweden

KS Biomedix makes considerable interim progress during 2000

Organon's antidepressant Remeron SolTab launched in U.S., copromotion of drug with Solvay reported

Isolation, structure determination and cytotoxic activity of AJI-9561

Phytopharm begins phase II evaluation of P-54 for IBD

Bridge Pharma/Immune Network alliance selects candidate for atopic dermatitis

Novel fluoroindolocarbazoles formed in rebeccamycin-producing microorganism

Clinical safety, pharmacokinetics and efficacy of amprenavir prodrug discussed in Chicago

Progen concludes phase Ib evaluation of PI-88

PRO-2000 protects against vaginal HIV transmission in monkeys

International patent covers use of thiazolidinediones for delaying or preventing type 1 diabetes

AstraZeneca prepares analgesics interacting with I2 receptors or sodium channels

Novel calcium channel antagonists described by Ortho-McNeil

Phenyl ureas for the treatment of chemokine-mediated diseases

Elan identifies new tetrapeptides that inhibit beta-secretase

Nonpeptide IL-2 production inhibitors and their use reported by Shionogi

WHI-P233, a new cytotoxic melamine derivative

Benzamide vasopressin antagonists in the Fujisawa pipeline

Peptide inhibitors of alphavbeta6 integrin disclosed by Merck KGaA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...